Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study

Psoriatic Arthritis

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Arthritis Res Ther.

Queiro R, Cañete JD, Montoro M, Gómez S, Cábez A, MAAPS study group.

doi: 10.1186/s13075-020-02168-1.

Psoriatic Arthritis

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis

Arthritis Rheumatol.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS

doi: 10.1002/art.40391.

Psoriatic Arthritis

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Ann Rheum Dis.

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML

doi: 10.1136/annrheumdis-2018-213463.

Psoriatic Arthritis

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

Health Qual Life Outcomes.

Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, Lim I, Eder L, Richette P, Weng MY, Queiro Silva R, Fallon L

doi: 10.1186/s12955-020-01422-z.

Psoriatic Arthritis

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

Semin Arthritis Rheum.

Coates LC, Nash P, Kvien TK, Gossec L, Mease PJ, Rasouliyan L, Pricop L, Jugl SM, Gandhi KK, Gaillez C, Smolen JS

doi: 10.1016/j.semarthrit.2020.03.015.

Psoriatic Arthritis

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients

J Rheumatol.

Orbai AM, McInnes IB, Coates LC, Husni ME, Gladman DD, Gossec L, Pricop L, Chambenoit O, Meng X, Mease PJ

doi: 10.3899/jrheum.190507.

Further Publications Rheumatology

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Arthritis Res Ther

Tanaka Y, Takeuchi T, Izutsu H, Kaneko Y, Kato D, Fukuda M, Rokuda M, Schultz NM

doi: 10.1186/s13075-021-02590-z

Psoriatic Arthritis

Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice

J Rheumatol

Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, Blanco R, Tofacitinib PsA Clinical Practice Collaborative Group.

doi: 10.3899/jrheum.201204

Psoriatic Arthritis

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study

Rheumatol Ther.

Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K

doi: 10.1007/s40744-019-0163-5.

Related content

Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study